Posted by powerchord on 27th of May 2008 at 02:33 pm
Alnylam Pharmaceuticals: Takeda deal at least as impressive
as the Roche deal on a comparable basis - Broadpoint
Capital(28.50 -0.95)
-Update-
Broadpoint Capital says that they view the
Takeda deal as equivalent or potentially more attractive than the
Roche deal and based on the market's early reaction, they believe
some investors may not be making the correct comparison in
assessing today's news. Firm says the headline of the Roche deal -
"$331 mln in upfront fees" - may make Takeda's "$150
mln in upfront fees" appear like a disappointment. However,
the firm says when comparing the two deals on an apples-to-apples
basis, they believe that the Takeda deal is at least as attractive
for ALNY as the Roche deal was.
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
blurb on ALNY -- watchlist stock
Posted by powerchord on 27th of May 2008 at 02:33 pm